Table 1. Baseline characteristics of 171 IMN patients.
| <65 years | 65–70 years | ≥71 years | P-value | |
| Number | 90 | 40 | 41 | |
| Baseline characteristics | ||||
| Age (years) | 57 (50–62) | 68 (66–69) | 75 (74–78) | |
| Male [n (%)] | 63 (70.0) | 28 (70.0) | 27 (65.9) | 0.882 |
| Body mass index (kg/m2) | 23.2 (21.2–25.8) | 23.2 (22.0–25.7) | 22.6 (21.1–24.6) | 0.440 |
| Systolic blood pressure (mmHg) | 129 (120–140) | 135 (125–158) | 138 (122–147) | 0.028 |
| Diastolic blood pressure (mmHg) | 77 (70–86) | 80 (70–86) | 76 (70–84) | 0.502 |
| Serum creatinine (mg/dL) | 0.77 (0.68–0.90) | 0.80 (0.68–0.99) | 0.95 (0.7–1.2) | 0.011 |
| eGFR (mL/min/1.73 m2) | 81 (70–97) | 73 (58–86) | 59 (46–81) | <0.001 |
| Serum albumin (g/dL) | 2.8 (2.1–3.5) | 2.5 (2.0–3.1) | 2.3 (1.9–2.8) | 0.014 |
| Urinary protein (g/day) | 4.2 (2.6–7.0) | 3.6 (2.6–7.6) | 5.1 (3.3–7.7) | 0.275 |
| Urinary protein >3.5 (g/day) [n (%)] | 29 (32.2) | 17 (42.5) | 11 (26.8) | 0.310 |
| Total cholesterol (mg/dL) | 279 (229–382) | 284 (239–400) | 297 (249–367) | 0.859 |
| Leg edema [n (%)] | 64 (71.1) | 29 (72.5) | 38 (92.7) | 0.020 |
| Pleural effusion [n (%)] | 12 (13.3) | 8 (20.0) | 13 (31.7) | 0.048 |
| Treatment | ||||
| ACE inhibitor or ARB therapy [n (%)] | 80 (88.9) | 39 (97.5) | 47 (90.2) | 0.268 |
| Immunosuppressive therapy | 0.893 | |||
| No immunosuppressants | 36 (40.0) | 17 (42.5) | 17 (41.5) | |
| Prednisolone [n (%)] | 17 (18.9) | 10 (25.0) | 8 (19.5) | |
| Prednisolone+Cyclosporine [n (%)] | 37 (41.1) | 13 (32.5) | 16 (39.0) | |
| Observational period (months) | 44 (20–86) | 31 (15–63) | 25 (11–54) | 0.021 |
NOTE: Median (interquartile range), Conversion factors for units: SCr in mg/dL to µmol/L, ×88.4; eGFR (mL/min/1.73 m2) = 194×Scr−1.094×Age−0.287×0.739 (if female), total cholesterol in mg/dL to mmol/L, ×0.02586.
Abbreviations: IMN, idiopathic membranous nephropathy; eGFR, estimated glomerular filtration rate; ACE inhibitor/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.